Rajnish Wellness Ltd
Incorporated in 2015, Rajnish Wellness Ltd manufactures and sells various ayurvedic medicinal products.[1]
- Market Cap ₹ 44.7 Cr.
- Current Price ₹ 0.44
- High / Low ₹ 1.26 / 0.39
- Stock P/E
- Book Value ₹ 1.01
- Dividend Yield 0.00 %
- ROCE -8.99 %
- ROE -6.74 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Stock is trading at 0.44 times its book value
- Debtor days have improved from 137 to 49.7 days.
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 9.16%
- Company has a low return on equity of -1.95% over last 3 years.
- Promoter holding has decreased over last 3 years: -6.89%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 25 | 28 | 42 | 14 | 13 | 26 | 26 | 77 | 49 | 142 | |
| 24 | 24 | 35 | 14 | 17 | 27 | 27 | 75 | 49 | 151 | |
| Operating Profit | 1 | 3 | 7 | 0 | -3 | -0 | -1 | 2 | 0 | -9 |
| OPM % | 5% | 12% | 16% | 1% | -24% | -1% | -4% | 3% | 0% | -6% |
| 0 | 1 | 0 | 0 | 4 | 1 | 2 | 0 | 1 | 1 | |
| Interest | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 1 | 4 | 6 | -1 | 0 | 0 | 1 | 1 | 0 | -8 |
| Tax % | 33% | 33% | 28% | -2% | 18% | 15% | 27% | 29% | 25% | -25% |
| 1 | 2 | 4 | -1 | 0 | 0 | 0 | 1 | 0 | -6 | |
| EPS in Rs | 0.94 | 0.06 | 0.08 | -0.01 | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 | -0.06 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 60% |
| 3 Years: | 77% |
| TTM: | 192% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -3800% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | -70% |
| 1 Year: | -52% |
| Return on Equity | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -1% |
| 3 Years: | -2% |
| Last Year: | -7% |
Balance Sheet
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 3 | 5 | 5 | 5 | 11 | 77 | 77 | 77 | 102 |
| Reserves | 1 | 3 | 18 | 17 | 17 | 12 | 6 | 7 | 7 | 1 |
| 3 | 4 | 5 | 8 | 0 | 0 | 10 | 5 | 0 | 0 | |
| 5 | 8 | 5 | 4 | 13 | 13 | 6 | 17 | 7 | 6 | |
| Total Liabilities | 8 | 18 | 32 | 33 | 35 | 35 | 99 | 106 | 91 | 109 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 8 |
| 8 | 18 | 32 | 33 | 35 | 35 | 99 | 106 | 88 | 101 | |
| Total Assets | 8 | 18 | 32 | 33 | 35 | 35 | 99 | 106 | 91 | 109 |
Cash Flows
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| -2 | -3 | -9 | -7 | 0 | -0 | -62 | 2 | -4 | -9 | |
| -0 | -0 | -0 | 0 | 0 | -0 | -0 | -0 | 9 | -7 | |
| 1 | 3 | 10 | 5 | -0 | 1 | 62 | -2 | -5 | 25 | |
| Net Cash Flow | -0 | -0 | 1 | -1 | 0 | 1 | -1 | -0 | 0 | 9 |
| Free Cash Flow | -2 | -3 | -9 | -7 | 0 | -0 | -62 | 2 | -4 | -9 |
| CFO/OP | -136% | -90% | -118% | -4,650% | -4% | -32% | 5,577% | 105% | -41,900% | 94% |
Ratios
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 59 | 182 | 164 | 318 | 460 | 224 | 287 | 160 | 201 | 50 |
| Inventory Days | 152 | 75 | 77 | 48 | 27 | 32 | 59 | 48 | 79 | 35 |
| Days Payable | 121 | 145 | 27 | 56 | 50 | 17 | 55 | 78 | 31 | 7 |
| Cash Conversion Cycle | 90 | 111 | 214 | 310 | 436 | 238 | 290 | 130 | 249 | 77 |
| Working Capital Days | 30 | 102 | 183 | 702 | 791 | 407 | 449 | 305 | 530 | 182 |
| ROCE % | 65% | 37% | 1% | 2% | 3% | 1% | 2% | 1% | -9% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Mix - Sexual Wellness Products % |
|
|||||||||
| Number of Permanent Employees Number |
||||||||||
| Geographic Reach - Number of States Served Count |
||||||||||
| Number of Distributors Number |
||||||||||
| Number of Super Stockists Number |
||||||||||
| Retail Store Presence (General Distribution) Number |
||||||||||
| Revenue Mix - Branded Electronics / Consumer Durables % |
||||||||||
| Number of C&F Agents Number |
||||||||||
| Number of Dava Discount Franchise Outlets Number |
||||||||||
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 1 Jun
- Declaration Of Results For The Quarter And Year Ended 31St March 2026. 30 May
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Saturday 30Th May, 2026
30 May - Board approved FY26 audited results; ₹9.70 crore debtors written off, year loss ₹628.72 lakh.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
28 May - Submitted Annual Secretarial Compliance Report for year ended 31 March 2026.
-
Board Meeting Intimation for Holding Board Meeting For Approval Of Audited Financial Results For The Quarter And Year Ended 31St March, 2026 And Other Matters.
25 May - Board meeting on May 30, 2026 to approve audited FY26 standalone financial results.
Business Overview:[1]
RWL is currently engaged in the business of selling various products in the categories ranging from the pharmaceutical products,
consumer durables to ayurvedic personal care products. Its focus area is pharmaceutical, energy revitalization, ayurvedic ethical medicines, personal care products, medicinal sexual enhancement products which are easily
available across the medical counters.